UK health regulator is the first country to approve gene editing using CRISPR – for conditions suffered mostly by immigrant populations

From here:

MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia - GOV.UK (www.gov.uk)

“A new treatment for sickle-cell disease and transfusion-dependent β-thalassemia has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for patients aged 12 and over after a rigorous assessment of its safety, quality and effectiveness.  “

That would be the same complete absence of “rigorous assessment of its safety, quality and effectiveness” that the MHRA applied to C19 mRNA injections – but allows the MHRA to continue its role as one of the main marketing arms of big pharma.

“Sickle cell disease is particularly common in people with an African or Caribbean family background. β-thalassemia mainly affects people of Mediterranean, south Asian, southeast Asian and Middle Eastern origin.”

I wonder why the powers that be chose these conditions to treat using gene editing. Not that I begrudge the treatment to third, fourth or fifth generation immigrants. Such a treatment would be a fantastic cure for hundreds of millions if not billions of people worldwide.

Just curious as to what is in the pipeline for people of “European descent” – that is white people.

I guess the West no longer needs the likes of Fauci and Gates to try their witches brew in foreign lands – the foreign lands are now resident in the UK!

“Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin. To do this, stem cells are taken out of bone marrow, edited in a laboratory and then infused back into the patient after which the results have the potential to be life-long.”

I wonder if a fourth or fifth booster of the C19 was included in the clinical trials. Hell, I wonder if cases of the horrible conditions that the gene edit is supposed to correct went up, went down or stayed the same during the scamdemic and roll0out of the C19 viral vector and C19 mRNA injections.

  Here’s a quote from Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA:

“I am pleased to announce that we have authorised an innovative and first-of-its-kind gene-editing treatment called Casgevy, which in trials has been found to restore healthy haemoglobin production in the majority of participants with sickle-cell disease and transfusion-dependent β -thalassaemia, relieving the symptoms of disease.”

What sort of majority of participants?

“In the clinical trial for sickle-cell disease, 45 patients have currently received Casgevy but only 29 patients have been in the trial long enough to be eligible for the primary efficacy interim analysis. Of these eligible patients, 28 (97%) were free of severe pain crises for at least 12 months after treatment.  “

Ok, so that’s pretty impressive! 97% of the people in the trial for long enough were pain free! That is, out of 45 enrolled in the trial, 29 were in long enough and 28 were cured!

“In the clinical trial for transfusion-dependent β-thalassemia, 54 patients have currently received Casgevy but only 42 patients have been in the trial long enough to be eligible for the primary efficacy interim analysis. Of these, 39 (93%) did not need a red blood cell transfusion for at least 12 months after treatment. The remaining three had more than a 70% reduction in the need for red cell transfusions.  “

Again, really impressive results 54 enrolled, 42 for long enough and 39 of those 42 were cured for a 93% cure rate!

No news of any side effects. Hmm. Keep your fingers crossed! This could be a game changer. Pardon me for not celebrating for those currently suffering who would view this as a miracle – reputations take more than a few minutes to recover.

 Here’s how it works:

“Casgevy is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory. Patients must then undergo conditioning treatment to prepare the bone marrow before the modified cells are infused back into the patient. After that, patients may need to spend at least a month in a hospital facility while the treated cells take up residence in the bone marrow and start to make red blood cells with the stable form of haemoglobin. “

Again, I wonder how many of the clinical trial participants were injected with C19 “vaccines” and how CRISPR and spike proteins interact.

(There are other gene editing tools other than CRISPR out there, but CRISPR seems to be the cheapest for the minimum quality.

Onwards!

Please subscribe or make a donation via Ko-fi – any amount from 3 bucks upwards. Don’t worry and God Bless, if you can’t or don’t want to. Ko-fi donations here: https://ko-fi.com/peterhalligan - an annual subscription of 100 bucks is one third less than a $3 Ko-fi donation a week!